Legend Biotech Corp
LEGN17.100USD
+0.400+2.40%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.16BMarket Cap
LossP/E TTM
More Details of Legend Biotech Corp Company
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Legend Biotech Corp Info
Ticker SymbolLEGN
Company nameLegend Biotech Corp
IPO dateJun 04, 2020
CEOHuang (Ying)
Number of employees2600
Security typeDepository Receipt
Fiscal year-endJun 04
Address2101 Cottontail Lane
CitySOMERSET
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08873
Phone17328505598
Websitehttps://investors.legendbiotech.com/
Ticker SymbolLEGN
IPO dateJun 04, 2020
CEOHuang (Ying)
Company Executives of Legend Biotech Corp
Name
Name/Position
Position
Shareholding
Change
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
+84321.00%
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
+7624.00%
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
+4200.00%
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-64246.00%
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Independent Director
Independent Director
--
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Mr. Wai Man (Philip) Yau, CPA
Mr. Wai Man (Philip) Yau, CPA
Independent Director
Independent Director
--
--
Dr. Fangliang (Frank) Zhang, Ph.D.
Dr. Fangliang (Frank) Zhang, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Patrick Casey, Ph.D.
Dr. Patrick Casey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Tomas J. (Tom) Heyman, Jr.
Mr. Tomas J. (Tom) Heyman, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Ye (Sally) Wang
Ms. Ye (Sally) Wang
Director
Director
84.32K
+84321.00%
Dr. Li Mao
Dr. Li Mao
Independent Director
Independent Director
7.62K
+7624.00%
Dr. Li Zhu, Ph.D.
Dr. Li Zhu, Ph.D.
Director
Director
4.20K
+4200.00%
Dr. Ying Huang, Ph.D.
Dr. Ying Huang, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
-64246.00%
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Independent Director
Independent Director
--
--
Mr. Xiaohui (Darren) Ji
Mr. Xiaohui (Darren) Ji
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
194.60M
76.30%
Europe
40.50M
15.88%
China
19.95M
7.82%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 21 hours ago
Updated: 21 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.65%
HHLR Advisors, Ltd.
3.41%
Westfield Capital Management Company, L.P.
3.30%
Suvretta Capital Management, LLC
2.07%
BlackRock Institutional Trust Company, N.A.
1.65%
Other
75.93%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.65%
HHLR Advisors, Ltd.
3.41%
Westfield Capital Management Company, L.P.
3.30%
Suvretta Capital Management, LLC
2.07%
BlackRock Institutional Trust Company, N.A.
1.65%
Other
75.93%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.49%
Investment Advisor/Hedge Fund
13.91%
Hedge Fund
8.09%
Corporation
1.22%
Research Firm
1.18%
Sovereign Wealth Fund
0.76%
Venture Capital
0.45%
Bank and Trust
0.28%
Insurance Company
0.19%
Other
50.44%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
552
88.44M
47.89%
-21.01M
2025Q3
547
88.17M
47.77%
-17.67M
2025Q2
545
89.45M
48.54%
-25.68M
2025Q1
566
91.15M
49.68%
-26.78M
2024Q4
546
104.37M
56.89%
-4.12M
2024Q3
521
96.19M
52.43%
-11.10M
2024Q2
501
96.66M
52.77%
-1.31M
2024Q1
490
91.55M
50.22%
-3.47M
2023Q4
482
91.08M
50.06%
-4.11M
2023Q3
468
90.50M
49.93%
-2.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
25.20M
13.65%
+2.07M
+8.97%
Sep 30, 2025
HHLR Advisors, Ltd.
6.30M
3.41%
+95.80K
+1.54%
Sep 30, 2025
Westfield Capital Management Company, L.P.
6.09M
3.3%
-378.06K
-5.84%
Sep 30, 2025
Suvretta Capital Management, LLC
3.82M
2.07%
+44.00K
+1.17%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.04M
1.65%
+188.42K
+6.60%
Sep 30, 2025
Deerfield Management Company, L.P.
2.96M
1.6%
--
--
Sep 30, 2025
Artisan Partners Limited Partnership
2.55M
1.38%
+425.68K
+20.06%
Sep 30, 2025
Genscript Biotech Corp
2.25M
1.22%
--
--
Dec 31, 2024
Fidelity Institutional Asset Management
2.50M
1.35%
-41.52K
-1.63%
Sep 30, 2025
Janus Henderson Investors
2.13M
1.15%
+32.35K
+1.55%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Harbor Health Care ETF
6.72%
Matthews Emerging Markets Sustainable Future Active ETF
3.84%
Matthews Emerging Markets Discovery Active ETF
3.64%
Global X Genomics & Biotechnology ETF
3.25%
Tema Oncology ETF
2%
Virtus LifeSci Biotech Products ETF
1.37%
KraneShares MSCI All China Health Care Index ETF
1.1%
JPMorgan Healthcare Leaders ETF
0.44%
iShares Biotechnology ETF
0.37%
Main Thematic Innovation ETF
0.36%
View more
Harbor Health Care ETF
Proportion6.72%
Matthews Emerging Markets Sustainable Future Active ETF
Proportion3.84%
Matthews Emerging Markets Discovery Active ETF
Proportion3.64%
Global X Genomics & Biotechnology ETF
Proportion3.25%
Tema Oncology ETF
Proportion2%
Virtus LifeSci Biotech Products ETF
Proportion1.37%
KraneShares MSCI All China Health Care Index ETF
Proportion1.1%
JPMorgan Healthcare Leaders ETF
Proportion0.44%
iShares Biotechnology ETF
Proportion0.37%
Main Thematic Innovation ETF
Proportion0.36%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
